Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic infl...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/11/6/1060 |
| _version_ | 1827662940821520384 |
|---|---|
| author | Eleftheria Galatou Elena Mourelatou Sophia Hatziantoniou Ioannis S. Vizirianakis |
| author_facet | Eleftheria Galatou Elena Mourelatou Sophia Hatziantoniou Ioannis S. Vizirianakis |
| author_sort | Eleftheria Galatou |
| collection | DOAJ |
| description | Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions. |
| first_indexed | 2024-03-10T00:34:56Z |
| format | Article |
| id | doaj.art-f22c40c6a5b944488e66c167fe074d5c |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T00:34:56Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-f22c40c6a5b944488e66c167fe074d5c2023-11-23T15:18:50ZengMDPI AGAntioxidants2076-39212022-05-01116106010.3390/antiox11061060Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based DrugsEleftheria Galatou0Elena Mourelatou1Sophia Hatziantoniou2Ioannis S. Vizirianakis3Department of Life & Health Sciences, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, CyprusDepartment of Life & Health Sciences, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, CyprusLaboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, GreeceDepartment of Life & Health Sciences, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, CyprusNonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.https://www.mdpi.com/2076-3921/11/6/1060nonalcoholic steatohepatitis (NASH)nonalcoholic fatty liver disease (NAFLD)atherosclerosisinflammationoxidative stressGLP-1 RAs |
| spellingShingle | Eleftheria Galatou Elena Mourelatou Sophia Hatziantoniou Ioannis S. Vizirianakis Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs Antioxidants nonalcoholic steatohepatitis (NASH) nonalcoholic fatty liver disease (NAFLD) atherosclerosis inflammation oxidative stress GLP-1 RAs |
| title | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs |
| title_full | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs |
| title_fullStr | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs |
| title_full_unstemmed | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs |
| title_short | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs |
| title_sort | nonalcoholic steatohepatitis nash and atherosclerosis explaining their pathophysiology association and the role of incretin based drugs |
| topic | nonalcoholic steatohepatitis (NASH) nonalcoholic fatty liver disease (NAFLD) atherosclerosis inflammation oxidative stress GLP-1 RAs |
| url | https://www.mdpi.com/2076-3921/11/6/1060 |
| work_keys_str_mv | AT eleftheriagalatou nonalcoholicsteatohepatitisnashandatherosclerosisexplainingtheirpathophysiologyassociationandtheroleofincretinbaseddrugs AT elenamourelatou nonalcoholicsteatohepatitisnashandatherosclerosisexplainingtheirpathophysiologyassociationandtheroleofincretinbaseddrugs AT sophiahatziantoniou nonalcoholicsteatohepatitisnashandatherosclerosisexplainingtheirpathophysiologyassociationandtheroleofincretinbaseddrugs AT ioannissvizirianakis nonalcoholicsteatohepatitisnashandatherosclerosisexplainingtheirpathophysiologyassociationandtheroleofincretinbaseddrugs |